•

An Interim Analysis of the tab-cel^® ALLELE study showed a 50 percent objective response rate (ORR) to tab-cel^® with independent oncologic and radiographic assessment (IORA) in patients with relapsed-refractory  EBV⁺ PTLD following hematopoietic cell transplants (HCT) or solid organ transplants (SOT) that had reached at least six months follow-up after achieving a response. This ORR is consistent with previously published data. The tab-cel^® safety profile is also consistent with previously published investigator assessed data, with no new safety signals.

•

In October, working under the Breakthrough Therapy Designation (BTD) for tab-cel^®, Atara presented a comprehensive data package to the FDA. The Company aligned with FDA on several key topics related to the regulatory package, including:

○

a rolling submission is acceptable for the biologics license application (BLA);

○

the Company can complete the BLA submission with the ALLELE study’s currently enrolled patients with at least six months follow-up for duration of response; and

○

the FDA will consider the following as supportive data to the pivotal study in the BLA clinical module: the Phase 2 trials conducted at Memorial Sloan Kettering (MSK); Atara’s Phase 2 multicenter expanded access protocol (201 EAP study); and the Single Patient Use (SPU) program.

●

Atara remains on track to initiate a BLA submission for patients with EBV⁺ PTLD by the end of 2020. The Company will continue engaging with the FDA as part of its rolling BLA and BTD status and expects to finalize the BLA submission in Q3 2021.

●

Following discussion with the PRIority MEdicines (PRIME) team and after EMA approval of the Pediatric Investigation Plan (PIP) expected in December 2020, Atara is on track to submit an EU marketing authorization application (MAA) for patients with EBV⁺ PTLD in the second half of 2021.

●

Data from the ALLELE study will be presented at an appropriate congress in 2021.

●

Atara initiated a tab-cel^® Phase 2 multi-cohort study in the third quarter of 2020 and expects to enroll the first patient in the fourth quarter of 2020. This study is being initiated concurrently in the U.S. and the EU.

●

The multi-cohort study is intended to enrich the evidence base with the goal of expanding the potential label for tab-cel^® in both treatment-naïve and previously treated patients (in six populations, including four within Immunodeficiency-Associated Lymphoproliferative Diseases (IA-LPDs) and two in other EBV-associated diseases).

●

Data demonstrating tab-cel^® was well-tolerated and showed encouraging clinical activity in patients with EBV⁺ AID-LPD and PID-LPD (Acquired and Primary Immunodeficiency LPDs) were featured in an e-poster at the European Society for Medical Oncology (ESMO) 2020 Virtual Congress held in September 2020. Specifically, in patients where previous treatments have failed, the objective response rates, including complete responses, were 33.3 percent (three out of nine patients) in AID-LPD and 37.5 percent (three out of eight patients) in PID-LPD groups. Tab-cel^® was generally well-tolerated with a favorable safety profile consistent with previously published clinical studies.

●

Data on tab-cel^® in patients with life-threatening complications stemming from persistent EBV viremia was accepted for presentation at the 62^nd American Society of Hematology (ASH) Annual Meeting and Exposition being held virtually December 5-8, 2020. These clinical data demonstrate that tab-cel^® was well-tolerated and showed encouraging clinical activity in this patient population with objective response rates ranging from 50 to 80 percent, warranting further investigation in the Phase 2 multi-cohort study. 

●

Atara’s Phase 1 clinical study of off-the-shelf, allogeneic ATA188 in patients with progressive forms of MS is ongoing, with encouraging data recently reported and more data from the Open Label Extension (OLE) to be periodically presented over the next 12 months including at the European Charcot Foundation (ECF) 28th Annual Meeting November 15-19, 2020.

○

Twelve-month data from all four cohorts in the Phase 1a portion of the study were presented at the MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting held in September 2020.

▪

These data demonstrated that ATA188 was well-tolerated across all four dose cohorts; patients who demonstrated sustained disability improvements (SDI) at any timepoint maintained it at all future timepoints; and a higher proportion of patients showed SDI with increasing dose (42 percent in Cohorts 3 and 4 (higher doses) vs 17 percent in Cohorts 1 and 2 (lower doses)).

▪

No dose-limiting toxicities and no fatal adverse events (AEs) have been reported. The safety profile has remained consistent with previously reported data.

▪

Data from the OLE with redosing at 12 months show that of the three patients enrolled in the OLE at that time that had SDI at 12 months, all maintained SDI at 15 months, including one patient evaluated at both 15 and 18 months who maintained SDI at both time points. A fourth patient demonstrated SDI during the OLE at 24 months.

▪

Atara also presented preclinical translational data at ACTRIMS-ECTRIMS that further support the proposed mechanism of action of ATA188 targeting EBV-infected B cells. These combined analyses of T cells comprising ATA188 are consistent with its proposed mechanism of targeting EBV-infected B cells by recognizing MS-relevant EBV antigens on these cells via defined T cell receptors (TCRs).

○

The double-blind randomized placebo-controlled trial (RCT), which enrolled its first patient in June 2020 continues active recruitment.

○

Given encouraging clinical results to date in ATA188 studies and the significant unmet medical need in progressive forms of MS, the Company is increasing its investment in the ATA188 program. Atara is expanding the size of the RCT to at least 64 patients, changing the primary endpoint of the study to disability improvement, and maintaining biological and functional endpoints; the design allows for the addition of the cohort 4 dose if desired.

○

Atara plans to discuss the Phase 1a data with the FDA by the end of this year, as well as the updated RCT study design, and potential opportunities for accelerated development of ATA188 for MS patients.

●

The open-label, single-arm Phase 1 clinical study of ATA2271, the Company’s second-generation autologous CAR T therapy targeting mesothelin (MSLN) that incorporates for the first time both a PD-1 DNR (dominant-negative programmed death-1 receptor) for intrinsic check-point inhibition and novel 1XX co-stimulatory domain, has been initiated for the treatment of advanced mesothelioma. Recently presented preclinical data have shown improved functional persistence and enhanced anti-tumor efficacy superior to first-generation MSLN CAR T. MSK is on track to enroll the first patient in the Phase 1 study in Q4 2020.

●

ATA3271 is an off-the-shelf, allogeneic CAR T therapy targeting MSLN using a PD-1 DNR and 1XX CAR co-stimulatory signaling domain through Atara’s EBV T-cell platform. In new preclinical data, ATA3271 demonstrates potent anti-tumor activity, functional persistence and significant survival benefit with no evidence of allocytotoxicity in vivo, suggesting that allogeneic MSLN-CAR-engineered EBV T cells are a promising approach for the treatment of MSLN-positive cancers. These data will be presented at the Society for Immunotherapy of Cancer (SITC) 35^th Anniversary Annual Meeting November 11-14, 2020.

●

A collaborative and successful pre-IND meeting with the FDA in October 2020 provided feedback to guide the IND filing in 2021.

●

IND-enabling studies are progressing with a package ready to be filed in 2021 for ATA3219, a potent next-generation off-the-shelf allogeneic CD19 CAR T utilizing the 1XX technology without the need for TCR gene editing through Atara’s EBV T-cell platform.

●

The first abstract to be presented on ATA3219 was accepted for presentation at the 62^nd American Society of Hematology (ASH) Annual Meeting and Exposition being held virtually December 5-8, 2020. These preclinical data for ATA3219 demonstrate persistence, polyfunctional phenotype and efficient targeting of CD19-expressing tumor cells with no evidence of allocytotoxicity in vivo. 

●

Cash, cash equivalents and short-term investments as of September 30, 2020 totaled $327.2 million, as compared to $347.7 million as of June 30, 2020.

○

September 30, 2020 cash balance of $327.2 million included $34.1 million net proceeds from at-the-market (ATM) facilities during the third quarter of 2020. Third quarter 2020 cash burn was $20.5 million, net of ATM proceeds.

●

Atara believes that its cash, cash equivalents and short-term investments as of September 30, 2020 are sufficient to fund planned operations into 2022.

●

Net cash used in operating activities was $53.0 million for the third quarter of 2020, as compared to $52.1 million for the same period in 2019.

●

The number of outstanding shares of common stock and pre-funded common stock warrants as of September 30, 2020 was 77,220,159 shares and warrants to purchase 5,755,487 shares, respectively.

●

Atara reported net losses of $74.3 million, or $0.92 per share, for the third quarter of 2020, as compared to $71.9 million, or $1.31 per share, for the same period in 2019.

●

Total operating expenses include non-cash expenses of $15.4 million for the third quarter 2020, as compared to $13.9 million for the same period in 2019.

●

Research and development expenses were $59.9 million for the third quarter of 2020, as compared to $53.5 million for the same period in 2019. The increase in the 2020 period was primarily due to costs associated with the Company’s continuing expansion of research and development activities, including: 

o

Clinical trial, manufacturing and process performance qualification activities related to tab-cel^®.

o

Higher employee-related costs from increased headcount. 

●

Research and development expenses include $8.2 million of non-cash stock-based compensation expenses for the third quarter of 2020, as compared to $7.0 million for the same period in 2019.

●

General and administrative expenses were $14.8 million for the third quarter of 2020, as compared to $19.0 million for the same period in 2019. The decrease in the 2020 period was primarily due to decrease in outside services costs and employee-related costs.

●

General and administrative expenses include $5.1 million of non-cash stock-based compensation expenses for the third quarter of 2020, as compared to $5.1 million for the same period in 2019.

September 30,

December 31,

2020

2019

Assets

Current assets:

Cash and cash equivalents

$

62,620

$

74,317

Short-term investments

264,565

184,792

Restricted cash - short-term

194

194

Prepaid expenses and other current assets

12,053

13,689

Total current assets

339,432

272,992

Property and equipment, net

51,954

54,176

Operating lease assets

12,069

14,007

Restricted cash - long-term

1,200

1,200

Other assets

877

567

Total assets

$

405,532

$

342,942

Liabilities and stockholders’ equity

Current liabilities:

Accounts payable

$

5,190

$

7,963

Accrued compensation

16,710

14,706

Accrued research and development expenses

8,883

8,341

Other current liabilities

5,272

5,733

Total current liabilities

36,055

36,743

Operating lease liabilities - long-term

13,129

14,136

Other long-term liabilities

2,413

1,282

Total liabilities

51,597

52,161

Commitments and contingencies

Stockholders’ equity:

Common stock

8

6

Additional paid-in capital

1,396,674

1,108,516

Accumulated other comprehensive income

527

220

Accumulated deficit

(1,043,274

)

(817,961

)

Total stockholders’ equity

353,935

290,781

Total liabilities and stockholders’ equity

$

405,532

$

342,942

Three Months Ended

September 30,

Nine Months Ended

September 30,

2020

2019

2020

2019

Operating expenses:

Research and development

$

59,877

$

53,538

$

179,096

$

154,457

General and administrative

14,829

19,018

48,259

61,525

Total operating expenses

74,706

72,556

227,355

215,982

Loss from operations

(74,706

)

(72,556

)

(227,355

)

(215,982

)

Interest and other income, net

364

661

2,049

3,502

Loss before provision for income taxes

(74,342

)

(71,895

)

(225,306

)

(212,480

)

Provision for income taxes

6

—

7

—

Net loss

$

(74,348

)

$

(71,895

)

$

(225,313

)

$

(212,480

)

Other comprehensive loss:

Unrealized (loss) gain on available-for-sale securities

(283

)

60

307

573

Comprehensive loss

$

(74,631

)

$

(71,835

)

$

(225,006

)

$

(211,907

)

Net loss per common share:

Basic and diluted net loss per common share

$

(0.92

)

$

(1.31

)

$

(3.21

)

$

(4.32

)

Weighted-average shares outstanding used to calculate

   basic and diluted net loss per common share

81,176

54,920

70,170

49,176